Background: Glutamate has been implicated in the pathophysiology of acute hypoxic-ischemic encephalopathy. Glutamine synthetase is an enzyme found in astrocytes that converts glutamate to its nontoxic analogue, glutamine. The present study tests the hypothesis that brain glutamine synthetase activity increases in response to acute hypoxic-ischemic insults and not in response to chronic hypoxia-ischemia or non-hypoxic-ischemic neurological disease.
G
lutamine synthetase is the primary enzyme responsible for detoxication of glutamate in the central nervous system. It converts this excitotoxin to its nontoxic metabolite, glutamine. 1 It is largely localized to astrocytes and, in the brain, is present in high concentration in the cerebellum. 2 Glutamate has been implicated in the pathophysiology of acute hypoxic-ischemic encephalopathy. 3 Astrocytes are often found in abundance in areas of acute hypoxic-ischemic insult and are thought to play a role in "rescuing" the surrounding neurons from the metabolic by-products of such injury. 4 Petito et al 5 have noted an increase in brain glutamine synthetase in rats subjected to acute bilateral carotid occlusion. We have measured glutamine synthetase activity in the cerebellum of 20 pediatric patients with acute or chronic hypoxic-ischemic injury or with neurological disease in which hypoxic-ischemic injury did not play a role. The present study demonstrates our ability to differentiate between acute hypoxicischemic injury and the other conditions, based on these enzyme levels.
Materials and Methods
Patient samples were divided into three categories: acute, those coming from patients with no prior history of neurological, cyanotic or ischemic cardiac, or respiratory disease who sustained an acute cardiorespiratory arrest (n=3); chronic, those coming from patients with a history of complex congenital heart disease or extracorporeal membrane oxygenation (duration 4-21 days), without a history of a defined clinically acute neurological or cardiorespiratory event (n=13); and non-hypoxic-ischemic, those coming from patients with central neurological disease not associated with cardiorespiratory failure (n=4). Table 1 provides the clinicopathologic profile of each patient from whom a specimen was obtained for analysis. Representative case histories are given in "Results." Autopsies were performed in the Pathology Department of Children's Hospital of Pittsburgh within 24 hours after death. In patients with acute cardiac or respiratory arrest, routine histopathologic staining demonstrated variable degrees of astrocyto- 
Criteria for inclusion in each of the groups are given in "Materials and Methods." M, male; F, female; ECMO, extracorporeal membrane oxygenation.
sis. Astrocytosis was also present in three of four specimens from patients with non-hypoxic-ischemic neurological disease. A sample of cerebellar tissue obtained at the time of autopsy was immediately frozen at -80°C and used for biochemical studies to determine glutamine synthetase activity.
Results were expressed as units of enzyme activity per gram of tissue (wet weight). A unit of enzyme activity is defined as the amount of enzyme that catalyzes the formation of 1 /j.mol of glutamic acid y-monohydroxamate in 15 minutes under the conditions given below.
A piece of cerebellar hemisphere (0.1-0.4 g) was removed with a scalpel from tissue previously maintained at -80°C. The sample was rapidly weighed and homogenized in 2 ml 0.15 M potassium chloride containing 10 mM /J-mercaptoethanol and 2 mM EDTA at 4°C. All subsequent preparative steps were performed at 4°C. The homogenate was centrifuged at 16,000g for 30 minutes. A 50-pJ aliquot of the supernatant was used to assay for glutamine synthetase activity by the method of Meister.
1 Briefly, the supernatant was added to a mixture (final volume 0.55 ml) containing 0.1 M imidazole-HQ, 25 mM 0-mercaptoethanoL, 50 mM sodium L-glutamate, 10 mM NaATP, 20 mM magnesium chloride, and 125 mM hydroxylamine adjusted to pH 12 with sodium hydroxide. Blanks consisting of all assay components except ATP were prepared for each sample. This mixture was incubated for 15 minutes at 37°C. The samples were then cooled to 4°C and 0.75 ml of a cold solution containing 0.37 M ferric chloride, 0.67 M hydrochloric acid, and 0.20 M trichloroacetic acid were added. The samples were then centrifuged at 3,000 rpm and 4°C for 10 minutes. The O D^ m of each supernatant (sample-blank) was determined at room temperature using a double-beam spectrophotometer. All analyses were performed in duplicate. Colorimetric analysis of a standard solution of glutamic acid y-monohydroxamate (Sigma Chemical Corp., St. Louis, Mo.) after derivatization with our ferric chloride solution indicated that the variability of the assay from day to day was in the range of ± 10%. Similarly, analysis of multiple pieces of cerebellar hemisphere from the same specimens revealed that the regional variation in glutamine synthetase was 6-8%. On any given day, samples from at least two of the groups were examined and in no instance were all of the members of a given group analyzed on a single day.
Results

Case Histories
Acute Patient 1: A 9-year-old male had been taking desipramine since a suicide attempt 6 months before his death. Three days before his death, he sustained a cardiorespiratory arrest after running laps at school. He underwent cardiopulmonary resuscitation, but was declared brain dead 3 days later. An autopsy revealed massive cerebral edema.
Chronic Patient 1: A 5-year-old female was well until 5 months before her death when she developed generalized muscle weakness, skin rash, and arthralgia. She was treated with corticosteroids for presumed dermatomyositis. One month before her death, she developed a dry cough that progressed to frank respiratory distress and cyanosis. A muscle biopsy at this time showed no evidence of inflammation and slight predominance of type I fibers. She died after 21 days of extracorporeal membrane oxygenation and corticosteroid treatment.
Non-hypoxic-ischemic Patient 1: A 1-year-old female weighed 2,180 g and had a head circumference of 30 cm (<5th percentile for age) at birth. She had Apgar scores of 9 at 1 minute and 9 at 5 minutes. Her psychomotor development was globally, severely, and consistently delayed, and she began having infantile spasms at 4 months of age; the latter evolved into a mixed seizure disorder. Her facies were dysmorphic, with upturned nares, short lips, and a flattened nasal bridge. At a chronic care facility, she was found dead in bed one morning. At autopsy, she was seen to have microcephaly with polymicrogyria and white matter hypoplasia accompanied by diffuse astrocytosis and microcalcifications. Figure 1 shows glutamine synthetase activity levels ranked in increasing order for ease of depiction. Even without statistical confirmation, it is obvious that samples from patients who sustained acute hypoxic-ischemic insults cluster at the high end of the glutamine synthetase activity spectrum (mean 6.5, range 5.4-7.2 units/g tissue). Statistical analysis by the Kruskal-Wallis one-way analysis of variance by ranks test 6 indicates that the three data groups do not come from one population (/><0.05). Although the sample size is too small to perform more meaningful tests to determine which of the three groups differs from the others, inspection of the data indicates that, with the exception of one "outlier," all of the values for patients with acute hypoxic-ischemic insults lie above those for patients 
FIGURE 2. Relationship of cercbcllar glutamine synthetase activity (units/g wet tissue wt) to the age (panel A) and sex (panel B) of the patient and to the number of hours between death and autopsy (panel Q . Neither age nor number of hours between death and autopsy correlated significantly with glutamine synthetase level (p>0.05, Spearman rank correlation test).
with chronic hypoxic-ischemic insults (mean 2.6, range 13-3.9 units/g tissue) or neurological disease without hypoxic-ischemic insult (mean 2.8, range 0.7-10.2 units/g tissue). Glutamine synthetase activity values for patients with chronic hypoxia-ischemia overlap with those for patients with non-hypoxic-ischemic neurological disease. Figure 2 shows that there was no correlation between the glutamine synthetase activity and the age (panel A) or sex (panel B) of the patient or the number of hours between death and autopsy (panel C) (p>0.05, Spearman rank correlation test). There was also no apparent correlation between the glutamine synthetase activity and the presence, absence, or degree of astrocytosis as noted on the autopsy report . Widespread astrocytosis of grey and white matter was prominent in the autopsies of both acute and chronic hypoxic-ischemic disease patients and in three of the four patients with nonhypoxic-ischemic neurological disease.
Discussion
One major role played by glia in the central nervous system is the maintenance of an appropriate extracellular milieu for neuronal function. 4 The detoxication of glutamate by glutamine synthetase in astrocytes and, perhaps, oligodendroglia, 7 is an important homeostatic process. Although many recent studies have focused on the effects of hypoxia and ischemia on the brain glutamate concentration, 3 little is known about the effects of these conditions on glutamate metabolism. In addition, the compensatory mechanisms of the brain in response to hypoxiaischemia are poorly understood.
The present study demonstrates that glutamine synthetase activity is increased in the cerebellum of children who have died of acute hypoxic-ischemic injury relative to those of children who sustained chronic hypoxia-ischemia or other chronic neurological insults. Our finding of comparable degrees of astrocytosis in patients with these conditions suggests that this increase in activity is not due simply to an increase in the number of glutamine synthetasecontaining cells, but rather to an induction of enzyme synthesis, an increase in enzyme half-life, or an intrinsic molecular change in the enzyme itself. It is possible as well that the severity of the hypoxicischemic insult was greater in the patients who died acutely than in those who tolerated a chronic insult. The finding of comparable levels of glutamine synthetase activity in patients with non-hypoxic-ischemic disease and those with chronic hypoxia-ischemia, and the absence of "intermediate levels" in the latter group, perhaps argues against this possibility and in favor of the existence of a different compensatory mechanism in the chronic situation.
Post-hypoxic-ischemic edema is not likely to be a confounding variable in the studies we have presented. Pathological evidence for edema was found only in those specimens from patients with acute hypoxic-ischemic insults. This edema would be expected to artifactually lower enzyme activity determinations expressed per gram of wet tissue weight. Our finding of elevated enzyme activity in these specimens is made all the more striking by this fact and may therefore quantitatively underestimate the degree of elevation of glutamine synthetase activity under these conditions. Similarly, reperfusion after ischemia has been reported to decrease glutamine synthetase activity in an animal model of cerebral ischemia. 8 The patients who were aggressively resuscitated in our study were those in the acute hypoxiaischemia group, and glutamine synthetase activity was elevated in this group. This makes it unlikely that the aggressiveness or rapidity of resuscitation is responsible for the glutamine synthetase activity changes we report.
Petito et al 5 have demonstrated that acute brain ischemia in rats results in an increase in glutamine synthetase activity and the number of glutamine synthetase immunoreactive cells in the cortex, striarum, and cerebellum. Our results are consistent with these findings, but also suggest that astrocytosis alone does not necessarily obligate a significant increase in glutamine synthetase activity.
The concentration of glutamate in the cerebellum 9 is fivefold to sixfold higher than the K,,, of the enzyme for this amino acid. 1 The enzyme is therefore likely to be near-saturated under physiological conditions, and a twofold to threefold difference in enzyme activity could therefore be of physiological as well as statistical significance.
Many other biochemical modulations have also been associated with changes in glutamine synthetase activity. Chronic hyperammonemia 10 and corticosterone exposure 11 lead to an increase in brain glutamine synthetase activity. However, our patient with hyperammonemia (maximum serum ammonia 525 fiM) due to ornithine transcarbamylase deficiency and the chronically stressed patients in our study all had glutamine synthetase activity levels well below those of patients who sustained acute hypoxiaischemia. Acute or short-term (1 week) ethanol administration, whether to cultured astrocytes 12 or in an animal model, 13 leads to a decrease in brain glutamine synthetase activity. The effects of chlorpromazine 14 and insulin 15 on glutamine synthetase activity vary markedly depending on the species and age of the animal from which cells are obtained and on the presence or absence of serum in the culture medium.
Our studies indicate that there was no significant correlation between glutamine synthetase activity and the number of hours between death and postmortem examination. Consistent with this finding, Bhargava and Telang 16 have reported that there is no change in brain glutamine synthetase activity over at least 12 hours after death. We have also found no correlation of sex or age with glutamine synthetase activity. Interestingly, although corticosterone markedly advances the induction of glutamine synthetase activity during ontogeny, neither testosterone, estradiol, nor progesterone are inducers of this enzyme.
11
These studies raise two major hypotheses that are amenable to direct testing in animal and tissue culture model systems; namely, that the increase in glutamine synthetase comes in response to an increase in extracellular glutamate, and that the increase in glutamine synthetase is the result of upregulation at the transcriptional level. Newly developed technology for in vivo microdiarysis could be used in animal models to measure extracellular concentrations of glutamate in specific local areas. The development of cDNA probes for mammalian glutamine synthetase mRNA 1718 will facilitate the testing for evidence of transcriptional upregulation of glutamine synthetase. From a clinical standpoint, it remains to be seen whether the changes we have observed in children can be generalized to adult populations. Furthermore, animal studies will help to distinguish the individual roles of hypoxia and ischemia in the mediation of increases in glutamine synthetase. Such studies will further our understanding of endogenous compensatory mechanisms and may pave the way for pharmacological interventions that might exploit such mechanisms. It is hoped that our studies, performed in the course of examining the role of glutamine synthetase in other diseases such as astrocytic neoplasia, will serve as an impetus for laboratories involved in examining biochemical changes in response to hypoxia and ischemia to confirm and further elucidate the mechanism of this phenomenon.
